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The objective of this paper is to systematically and critically review the available literature on the effects
of subthalamic nucleus (STN) stimulation on the quality of life (QoL) of patients with Parkinson’s disease
(PD). A systematic review of the literature published from 1993 to May 2013 was conducted using
PubMed, Cochrane Library, MEDLINE, EBSCO host, CINAHL, and CEPS þ CETD, in addition to hand
searching selected periodicals and checking reference lists. The review included randomized and non-
randomized controlled trials, published in English, comparing STN stimulation with the best medical
therapy on the QoL of patients with PD. The time over which QoL was evaluated ranged from baseline to
24 months. Two reviewers independently assessed the study quality and the extracted data. Of the over
273 potential studies examined, we identiﬁed seven pertinent articles published between 2002 and 2013
involving 1193 participants. Six of the seven studies were randomized controlled trials (RCTs). Almost all
reported statistically signiﬁcant outcomes. All the studies using QoL outcome variables included the
Parkinson’s Disease Questionnaire-39 (PDQ-39) (n ¼ 7) and two also used the Short Form-36 (SF-36)
questionnaire (n ¼ 2). There was signiﬁcant improvement in QoL (PDQ-39) up to 6 months following
STN-deep brain stimulation (DBS) in three RCTs and in one nonrandomized trial and up to 12, 18, and 24
months postoperatively in one RCT each, compared with no improvement in the medical therapy groups.
There was a 22% improvement in the physical summary score on the SF-36 questionnaire versus no
change in the drug-only group. The quality of the trials was limited by the potential for bias associated
with inadequate concealment, no reported intention-to-treat analysis, and small sample size. Moreover,
there were problems in some studies with confounding factors. The main points to emerge from this
review of studies on STN-DBS in patients with PD demonstrate an overall positive effect on QoL. Based on
these studies, the beneﬁts may last for 2 years. The review clearly highlights the need for well-designed,
methodologically standardized outcome measurement research into the effectiveness of STN stimulation
in PD.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Parkinson’s disease (PD) is a common progressive bradykinetic
disorder that can be accurately diagnosed. It is characterized by
severe pars compacta nigral cell loss and accumulation of aggre-
gated alpha-synuclein in speciﬁc brain stem, spinal cord, and
cortical regions [1]. The crude prevalence rate of PD has been re-
ported to range from 15 to 12,500 per 100,000, and the incidence ofry, Buddhist Tzu Chi General
lien, Taiwan. Tel.: þ886 3
. Chen).
ddhist Compassion Relief Tzu ChiPD from 15 to 328 per 100,000, with the disease being less common
in Asian countries [2]. There is currently no cure for the disease, but
symptoms related to PD can be treated by both medicine and sur-
gery. Since the late 1960s, levodopa and other dopaminergic-based
therapies have been the basis of medical treatment for PD. Despite
effective control of symptoms, especially in the early stages of the
disease, the use of levodopa and other dopaminergic therapies
eventually results in motor ﬂuctuations and dyskinesia, side effects
that may be equal to or worse in severity than the motor impair-
ment of the disease itself [3]. Given these limitations, surgical
therapy has emerged as an additional option for PD treatment and
has provided PD patients with improved clinical control of symp-
toms and/or reduced adverse events.Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Electronic databases searched.
Database Data searched
PubMed 1993 to May 2013 March 2013 to May 2013
Cochrane Library 1993 to May 2013 March 2013 to May 2013
MEDLINE via Ovid online 1993 to May 2013 March 2013 to May 2013
EBSCO host 1993 to May 2013 March 2013 to May 2013
CINAHL 1993 to May 2013 March 2013 to May 2013
CEPS þ CETD 1993 to May 2013 March 2013 to May 2013
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thalamotomies for PD in the 1950s and 1960s. Early in surgical
therapy, many DBS groups implanted the ventral intermediate
(Vim) nucleus of the thalamus target in PD patients. However, this
approach gradually fell out of favor with realization that stimula-
tion of the Vim was most effective for upper extremity tremors,
with much less measured efﬁcacy for the other cardinal motor
features of PD (e.g., bradykinesia and rigidity) [4]. The globus pal-
lidus interna (GPi) emerged in the early 1990s as a potential target
for DBS therapy. However, the GPi target was quickly overtaken by
the subthalamic nucleus (STN) [5,6], following studies showing that
STN lesions were very effective in reducing major motor distur-
bances in parkinsonian primates [7] and that drastic reduction in
medication could be realized in some human cases [8]. At present,
STN-DBS is the most common surgical procedure for PD [3].
Because levodopa-responsive parkinsonian symptoms are
improved by high-frequency stimulation of the STN [3,9], neuro-
stimulation has become an established treatment for advanced PD
with medically intractable ﬂuctuations and dyskinesia. It is typi-
cally used after the disease has been present for 11e13 years [10e
12] when quality of life (QoL), social adjustment (psychosocial
competence) [13], and professional activity are already severely
impaired [14].
Several randomized, controlled trials of DBS have conﬁrmed its
efﬁcacy [10,11,15,16]. The end points of these trials included QoL,
the severity of motor symptoms when the patient was not taking
medication, and the number of hours per day spent in the “on” state
without dyskinesia. QoL signiﬁcantly improves in the majority of
patients after STN-DBS, but not in all [17]. The reasons for this may
bemultidimensional, but their identiﬁcation seems to be important
for optimized treatment results [18]. When movement disorders
cannot be adequately controlled with available treatments, there
may be profoundly detrimental effects on patients’ health-related
QoL (HRQoL) [19]. Therefore, the focus has shifted to the mea-
surement of patient-based outcomes to assess (1) the impact of the
disease and (2) the efﬁcacy of interventions. Moreover, the major
patient-based outcome is QoL or HRQoL [20].
Despite a rapid increase in the number of studies on STN-DBS
in people with PD, there is some disagreement on the impact of
STN stimulation. The New England Journal of Medicine Quality
of Life Study revealed improvements in Parkinson’s Disease
Questionnaire-39 (PDQ-39) scores, including subscales for
mobility, activities of daily living (ADLs), emotional well being,
stigma and bodily discomfort, after treatment with bilateral STN-
DBS [10]. This review seeks to identify studies that provide infor-
mation about outcomes of STN-DBS in patients with PD, and
summarize and compare QoL and other results from these studies
with the disease-speciﬁc PDQ-39 [21,22].There are two types of
HRQoL instruments, namely, generic and disease speciﬁc [23].
Generic instruments are multidimensional questionnaires that
cover a variety of areas. Therefore, this study used disease-speciﬁc
and generic instruments as useful tools. They provide more infor-
mation about the impact of STN stimulation on the QoL of patients
with PD.
The aim of this study is to systematically and critically review
the available literature on the impact of STN stimulation on QoL
outcomes among patients with PD.
2. Materials and methods
2.1. Search methods
A search strategy was developed to identify published studies
on the impact of STN stimulation on QoL or HRQoL in patients with
PD. An expert panel was established to guide the systematic reviewprocess. The search for eligible studies was comprehensive and
involved multiple strategies. Data were sought from published
studies in English and Chinese language journals. Searches were
limited to human-based studies. An initial limited literature search
of PubMed was conducted to identify relevant keywords contained
in title, abstract, and study descriptions. We used medical subjects
headings to select search terms. STN-DBS was ﬁrst applied for PD in
1993 [24]. Similar strategies were used in searching other biblio-
graphic databases for relevant research articles published between
1993 and May 2013 (Table 1). In addition, we reviewed references
from articles identiﬁed in the aforementioned searches to include
any additional papers related to outcomes of DBS that may have
been missed.
We used the following terms as keywords: “deep brain stimu-
lation”, “subthalamic nucleus stimulation”, “neurostimulation”,
“quality of life”, “health-related quality of life”, and “Parkinson’s
disease”. The keywords used to search for publications that met the
design criteria were “randomized controlled trial/s”, “controlled
trial/s”, “random allocation”, “clinical trials”, and “random”.
The reference lists of all relevant articles were checked. The
literature search was carried out on May 31, 2013, and papers were
included in the review if retrieved before July 1, 2013.
To identify potentially eligible articles, two reviewers (J.-L.J. and
S.-T.T.) screened the titles and abstracts obtained from the elec-
tronic search strategy. Retrieved abstracts were further scrutinized
to include only studies that had at least 6 months of follow-up time.
In addition, authors scanned abstracts to ensure the presence of
outcome data, including presurgical and postsurgical QoL or HRQoL
scores. If a decision could not be made regarding the eligibility for
inclusion, the full text of the article was examined. Full-length ar-
ticles of all selected abstracts were retrieved and assessed by the
same reviewers for the following inclusion criteria.
2.2. Inclusion criteria
2.2.1. Types of studies
The selection criteria were studies restricted to randomized or
nonrandomized control trials on the effectiveness of STN-DBS for
the treatment of idiopathic PD. Randomized controlled trials (RCTs)
provide the best possible evidence on clinical outcomes. If ﬁltering
only identiﬁed a small number of RCTs, clinical controlled trials
could also be included. The use of nonrandomized data required
careful consideration of the comparability of the treatment and
control groups in those studies. Retrieved abstracts were further
scrutinized to include only those studies with at least 6 months of
follow-up time.
Excluded from the review were investigations that primarily
examined factors that predicted changes in QoL and other sys-
tematic reviews relevant to this topic [20,25]. Studies documenting
only nonmotor outcomes (e.g., cognitive function) or surgical pa-
rameters (e.g., microelectrode recording) were not considered in
our review. We also excluded publications if the electrode im-
plantation site was not the STN. Only articles meeting the inclusion
criteria were retained for analysis.
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Studies on human patients were included, while animal and
laboratory studies were excluded. There were a number of animal
and laboratory studies in this area, but the generalizability from
laboratory animal models to clinical patients is problematic.
2.2.3. Type of intervention
The intervention of interest was STN-DBS can change the QoL in
patients with idiopathic PD.
2.2.4. Type of outcome measurement
A generic or disease-speciﬁc QoL measure was applied as a
primary or secondary variable of interest.2.3. Critical appraisal
The screening of relevant studies for inclusion was conducted
independently by two reviewers using titles, publication years, and
abstracts. To assess the quality of the studies, a checklist developed
by Melnyk and Fineout-Overholt [26] was used in the critical
appraisal of RCTs. A total of seven study elements were critically
appraised to determine a study quality score. Each item had a
possible score of 0e2 (0 for not done, 1 for unclear, and 2 for done),
with possible total scores ranging from 0 to 30. Any study with a
quality score below 60% (raw score < 18) of the total possible score
was eliminated from this review.2.4. Data extraction and synthesis
A standardized data-extraction form was developed to obtain
key information relevant to the review. The data from each
selected study were transferred to a data-extraction sheet. For all
the trials, baseline data, study design, statistical analysis, ethics,
participants’ characteristics, and outcome measures were extrac-
ted. To extract relevant data from included studies accurately and
without bias, the same reviewers who had previously conducted
the study assessment performed the data extraction. Standardized
mean differences (for continuous data) and their 95% conﬁdence
intervals were calculated for each individual study. For cases in
which group data were heterogeneous and not suitable for meta-
analysis, a narrative summary was used. Discrepancies in the
quality appraisal form and completed data extraction were dis-
cussed using a priori decision rules to complete the assessment
form.3. Results
3.1. Selection of studies
The number of hits on the aforementioned speciﬁed databases
using the initial combined search terms “deep brain stimulation
or subthalamic nucleus stimulation or neurostimulation and
quality of life or health-related quality of life and Parkinson’s
disease” was as follows: PubMed (n ¼ 155), Cochrane Library
(n ¼ 0), MEDLINE (n ¼ 85), EBSCO host (n ¼ 31), CINAHL (n ¼ 2),
CEPS þ CETD (n ¼ 0). The full texts of the remaining 32 articles
were retrieved and assessed for inclusion. One additional study
was identiﬁed from searches of the reference lists of the retrieved
articles. Items were then reviewed to see whether they could
be included based on their reporting of a study on an STN-DBS
intervention for PD. A total of seven papers remained that met
our critical appraisal score between 23 and 28 (Table 2)
[10,11,14,15,18,27,28].3.2. Methodological quality of the research
Included papers were published between 2002 and 2013. There
were six published RCTs [10,11,14,15,18,27] and one controlled
before and after trial [28]. J.-L.J. and S.-T.T. examined the papers that
described nonrandomized, controlled prospective before and after
trial approach (e.g., Just and Ostergaard 2002) [28]. All studies
compared subthalamic DBS with best medical treatment. In three
studies, the intention-to-treat principle, last observation carried
forward, and sample-size estimation were applied in the analysis
[10,14,15]. The studies originated from six countries, the United
Kingdom, France, Germany, Austria, Denmark, and the United
States. All seven trials reported that the type of health-care setting
in which the study was conducted was a hospital. No studies
mentioned allocation concealment, and all but two studies re-
ported that movement-disorder neurologists carried out the
outcome measurements [14,15].
3.3. Characteristics of participants and intervention
All seven trials had different numbers of participants ranging
from 20 [27] to 366 [11], with a combined total of 1193. The studies
compared STN-DBS (n ¼ 527) or STN-DBS combined with GPi
stimulation (n ¼ 65) [11,15] versus medical therapy. The mean age
was 59.1 years (range: 52.2e62.4; 71.18% were male) and the mean
disease duration was 11.9 years (range: 7.3e16.0) in the studies
reporting these variables. Two trials did not have details of the
participants’ ages or sexes. All 1193 participants in the review had a
diagnosis of idiopathic PD. Participants had moderate to severe PD
with Hoehn and Yahr (H and Y) [29] staging (range: 2e5). One
report [11] included individuals with mild to moderate PD (H and Y
 2) within their sample although these individuals made up less
than 10% of the total sample in the study. The time over which QoL
was evaluated ranged from baseline to 24 months.
3.4. Outcome measures
The instruments that are used to measure QoL or HRQoL in PD
can be classiﬁed into two categories, namely, disease-speciﬁc and
generic measure of health status. Themost frequently used disease-
speciﬁc measure was the PDQ-39, and the Short Form-36 (SF-36)
was selected as a generic tool. All the studies using the QoL
outcome variables included the PDQ-39 (n ¼ 7) and two used the
SF-36 questionnaire (n ¼ 2) [10,18]. The PDQ-39 is a questionnaire
with 39 items covering the following eight discrete dimensions:
mobility (10 items), ADLs (6 items), emotional well-being (6 items),
stigma (4 items), social support (3 items), cognition (4 items),
communication (3 items), and bodily discomfort (3 items). The
score for each item ranges from zero (0) to four (4) with never ¼ 0;
occasionally¼ 1; sometimes¼ 2; often¼ 3; and always¼ 4 (range of
scores: 0e156). A higher score signiﬁes a poorer QoL [30]. The SF-36
is a measure of health status consisting of 36 questions with scores
in eight domains, namely, physical function (10 items), physical
performance (4 items), physical pain (2 items), general health (5
items), vitality (4 items), social function (2 items), emotional per-
formance (3 items), and mental health (5 items). Summary scores
for physical and mental function can be calculated, with higher
scores representing better health status [31].
3.5. Changes in QoL as measured by the PDQ-39
There was a signiﬁcant improvement in QoL (PDQ-39) up to 6
months following STN-DBS in three RCTs [10,15,18] and in one
nonrandomized trial [28], and up to 12, 18, and 24 months post-
operatively in one RCT each [11,14,27], compared with no
Table 2
Details of included studies.
Author/QS/country Design Participant Treatment Outcome measured Results
Schuepbach et al
(2013) [14]
QS ¼ 27/30
Germany and France
1. A randomized,
multicenter,
parallel-group
design.
2. Assessments
were scheduled at
baseline and at 5,
12, and 24 months.
A total of 251 patients
with PD.
Neurostimulation plus
medical therapy
(n ¼ 124) versus
medical therapy alone
(n ¼ 127).
STN-DBS plus
medical therapy
versus medical
therapy.
1. PDQ-39 1. For the primary outcome of quality of life,
the mean score for the neurostimulation
group improved by 7.8 points, and that for
the medical-therapy group worsened by 0.2
points (between-group difference in mean
change from baseline to 2 years, 8.0 points;
p ¼ 0.002).
Daniels et al (2011)
[18]
QS ¼ 25/30
Germany
1. Multicenter
randomized,
controlled trial.
2. Assessments
were scheduled at
baseline and at 6
months.
A total of 121 patients
with PD. STN-DBS
group (n ¼ 61).
Control group (n ¼ 60).
STN-DBS versus
best medical
treatment.
1. PDQ-39 summary
index.
2. PCS of SF-36.
1. PDQ-39 summary index improved after
STN-DBS for 57% of the patients. Patients
with improvement in QoL showed
signiﬁcantly higher cumulative daily ‘‘off’’
time.
2. The changes in SF-36 PCS are negatively
correlated with the UPDRS dyskinesia score
at baseline, and therefore, fewer dyskinesia
cases are associated with greater QoL
improvement.
Williams et al (2010)
[11]
QS ¼ 27/30
UK
1. Randomized,
open-label trial.
2. Assessments
were scheduled at
baseline and at 12
months.
366 patients from 13
neurosurgical centers
in the UKwere assigned
to the surgery group
(n ¼ 183) or to the best
medical therapy group
(n ¼ 183).
STN-DBS (n ¼ 174)
or GPi DBS versus
best medical
therapy.
1. PDQ-39 summary
index.
1. At 1 year, the mean improvement in PDQ-
39 summary index score compared with
baseline was 5.0 points in the surgery group
and 0.3 points in the medical therapy group
(difference: e4.7; 95% CI: e7.6 to e1.8;
p ¼ 0.001).
Weaver et al (2009)
[15]
QS ¼ 28/30
USA
1. Randomized
controlled trial.
2. Assessments
were scheduled at
baseline and at 6
months.
A total of 255 patients
with PD.
Bilateral deep brain
stimulation of the STN
(n ¼ 60) or GPi (n ¼ 61)
versus best medical
therapy (n ¼ 134).
Bilateral STN or GPi
DBS versus best
medical therapy.
1. PDQ-39 1. Compared with the best medical therapy
group, the DBS group experienced
signiﬁcant improvements in the summary
measure of quality of life and on seven of
eight PDQ-39 scores (p < 0.001).
Schüpbach et al
(2007) [27]
QS ¼ 25/30
France
1. Prospectively
randomized.
Matched for age,
duration and
severity of disease,
and impairment in
socioprofessional
functioning.
2. Assessments
were scheduled at
baseline and at 18
months.
A total of 20 patients
with PD. Patients were
assigned to undergo
bilateral STN-DBS
(n ¼ 10) or receive
medical treatment
(n ¼ 10).
Bilateral STN-DBS
versus optimized
medical treatment.
1. PDQ-39 1. QoL was improved by 24% in surgical and
0% in nonsurgical patients (p < 0.05).
Deuschl et al (2006)
[10]
QS ¼ 25/30
Germany
Austria
1. Unblinded trial
with a randomized-
pairs design.
2. Assessments
were scheduled at
baseline and at 6
months.
78 pairs of patients
(n ¼ 156 patients) with
PD were assigned to
treatment.
Bilateral STN-DBS
versus best medical
therapy.
1. PDQ-39 summary
index.
2. SF-36 physical and
mental summary
scores.
1. For the neurostimulation group, the PDQ-
39 summary index score was 41.8  13.9 at
baseline and 31.8  16.3 at 6 months. In the
medication group, the PDQ-39 score was
39.6  16 at baseline and 40.2  14.4 at 6
months. The results show an improvement
of about 25% in the neurostimulation group
compared with almost no change in the
medication group. Neurostimulation also
resulted in a 22% improvement in the SF-36
physical summary score.
Just and Ostergaard
(2002) [28]
QS ¼ 23/30
Denmark
1. Nonrandomized,
controlled
prospective trial.
2. Assessments
were scheduled at
baseline (T0), at 3
months (T3), and at
6 months (T6).
A total of 24 patients
with PD. STN-DBS
(n ¼ 11) and similar
group of patients
awaiting surgery
(n ¼ 13).
STN-DBS versus
nonsurgery.
1. PDQ-39 1. For the PDQ-39 scores from T0 to T3, the
surgery group demonstrated signiﬁcant
improvement for subscales mobility, ADLs,
and bodily discomfort, in addition to
signiﬁcant improvement by 14.0 points in
the PDQ-39 summary index. From T0 to T6,
the surgery group improved by 16.1 points.
The nonsurgery group demonstrated no
signiﬁcant changes in the PDQ-39 summary
index or in any of the subscales from T0 to T3
or from T0 to T6.
ADLs ¼ activities of daily living; CI ¼ conﬁdence interval; DBS ¼ deep brain stimulation; GPi ¼ globus pallidus interna; PCS ¼ physical composite score; PD ¼ Parkinson’s
disease; PDQ-39 ¼ Parkinson’s Disease Questionnaire-39; QoL ¼ quality of life; QS ¼ quality score; SF-36 ¼ Short Form-36; STN ¼ subthalamic nucleus; UPDRS ¼ Uniﬁed
Parkinson Disease Rating Scale.
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resulted in improvements of 24e38% in the PDQ-39 subscales for
mobility, ADLs, emotional well-being, stigma, and bodily discom-
fort [10]. Another study showed signiﬁcant improvements in
mobility, ADLs, and bodily discomfort [28].
3.6. Changes in QoL as measured by the SF-36
There was a 22% improvement in the physical summary score of
the SF-36 questionnaire versus no change in the drug-only group
[10]. Daniels et al (2011) reported that the changes in SF-36 physical
composite score were negatively correlated with the Uniﬁed Par-
kinson’s Disease Rating Scale dyskinesia score at baseline, and so
less severe dyskinesia was associated with greater QoL improve-
ment [18].
4. Discussion
After DBS treatment, patients can expect improvements in QoL.
This review conﬁrmed previous uncontrolled studies on QoL after
STN-DBS, which consistently reported improvements in the PDQ-
39 [19,32].
4.1. Limitations of the review
The systematic search and selection process revealed only seven
studies inwhich these effects were rigorously examined. There was
no limitation of language in the search strategy. However, no pa-
pers were found in languages other than English. There are, of
course, scientiﬁc journals in other countries and in other languages
to which we have no access or knowledge. Another limitation of
this systematic review is that only accepted full-paper studies were
reviewed. This decision was made for practical reasons based on
the need for detailed, original study data to conduct a systematic
review. It is acknowledged that inclusion of these studies may have
inﬂuenced the ﬁndings of this systematic review. In addition, the
quality-assessment tool used here was developed by Melnyk and
Fineout-Overholt [26]. For RCTs, a large number of appraisal tools
exist that have been subject to varying degrees of evaluation.
However, how best to distinguish good quality before and after trial
studies from poor quality ones is less clear. There is also little in-
formation on how best to appraise before and after trial studies.
4.2. Methodological issues
Wemay havemissed some studies as our literature researchwas
restricted to only certain databases. There were a variety of meth-
odological weaknesses in the studies in this review. Common
limitations were small sample size and limited information on the
setting of the study, and the qualiﬁcations and training of the in-
vestigators, and a lack of reliability and validity outcome measures.
A more general limitation of this approach was seen in two studies
that reported only a small sample size, which favored Type-II errors
(no rejection of false null hypothesis) although most of the in-
terventions demonstrated a signiﬁcant effect. The majority of
studies provided no information on statistical power or effect size
to adequately detect effect outcomes. Only three studies were
deﬁnitely powered to use QoL as the primary outcome parameter
[10,11,14]. Furthermore, the majority of studies did not report the
intention-to-treat analysis and/or last observation carried forward
analysis. This highlights the need for replication of studies to fully
evaluate the effectiveness of STN-DBS.
Although there were problems with the methodological quality,
these studies were not necessarily weak. Methodological weak-
nesses, such as missing details, may be due to the writing process.However, the format of reporting and lack of details can result in a
lack of clarity.
4.3. Inﬂuences of STN-DBS on QoL
Previous reviews have shown that the effects of DBS on HRQoL
correlate with improvement in motor complications, although
psychological aspects may also play a role [19]. The good response
of subthalamic DBS on the PDQ-39 summary index was also
conﬁrmed by another review [3]. A meta-analysis of PDQ-39
summary index scores showed that the results of the trials are
generally consistent with each other (test for heterogeneity,
p ¼ 0.2), although there is evidence of heterogeneity of the treat-
ment effect between the trials with 6 months of follow-up and
those with 12 months of follow-up (test for interaction, p ¼ 0.04)
[11]. It is worth considering the potential alternative explanations
based on differences in the trial designs. It is possible that there is a
large immediate effect of surgery, whether real or, in part, related to
an early so-called honeymoon effect [33]. If the beneﬁts of surgery
are relatively transient, its long-term value could be called into
question [11].
Effective treatment is and will continue to be of major impor-
tance in the rapidly enlarging global populationwith PD. Therefore,
what can be concluded in terms of clinical practice? Clearly, motor
and nonmotor symptom controls are important to enhance QoL.
Althoughmost studies have concluded that DBS is a safe procedure,
the risk of procedure-related complications is not negligible. There
was one procedure-related death [11]. One study also found a small
negative effect of DBS on some aspects of cognitive function and
verbal ﬂuency [15]. Gronchi-Perrin et al [34] found that, on average,
patients perceived their postoperative ability to communicate to
have worsened and their performance on ADLs to have remained
unchanged. The clinical signiﬁcance of these effects remains to be
explored. In the absence of information from RCTs with a longer
duration of follow-up, expert centers could provide valuable
observational data on the frequency and clinical signiﬁcance of
adverse outcomes following DBS.
5. Conclusion
The main point to emerge from this review is that these studies
on STN-DBS in patients with PD demonstrate an overall positive
effect on QoL. Based on these studies, the beneﬁts may last for 2
years. Nevertheless, a few studies had small samples, and one was
not an RCT. Furthermore, this type of investigationmight be fraught
with the problem of confounding variables.
5.1. Implications for research
This review clearly demonstrates the need for further investi-
gation. First, research needs to use standardized interventions and
outcomemeasures, including analysis of patient-relevant outcomes
such as motor function, disease severity, adverse events, and cost
effectiveness. Second, qualitative data on patient expectations, and
subjective experiences would reveal additional dimensions that
can be tested in rigorous intervention studies. Such studies could
clarify the types of impacts on patients living with PD and changes
between presurgery and postsurgery. This should be included in all
PD treatment protocols. Third, QoL depends on the severity of the
disease, disability, severity of dyskinesia, depression, pain, and
some other factors [35]. As we begin to explore the value of
treatment interventions and try to draw conclusions on its efﬁcacy,
more research will be needed on the factors affecting outcomes in
intervention trials. Finally, all of the studies in this review were
conducted in Western countries. Therefore, there is a distinct need
J.-L. Jiang et al. / Tzu Chi Medical Journal 26 (2014) 15e2020to conduct quality clinical studies in health-care environments in
Eastern countries.References
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